Concurrent validation turns up in project meetings as a way to rescue a launch date.
The plan has three validation batches, the first is made, so the proposal is to release it now and finish the program while it sells.
EU GMP Annex 15 (2015) does let batches reach the market before validation is complete, and it says when. In exceptional circumstances, where there is a strong benefit-risk ratio for the patient, it may be acceptable not to complete a validation program before routine production starts, and concurrent validation could be used. The decision must be justified, documented in the validation master plan and approved by authorised personnel.
The test in that sentence is the patient's benefit and risk. A medicine in short supply that patients depend on can meet it. A project three months behind cannot, because the benefit is the company's. Its answer is in the schedule, with the validation batches and their laboratory time in the first baseline.
When the route is taken, there should be sufficient data to support the conclusion that each batch is uniform and meets its acceptance criteria, documented and available to the Qualified Person before certification.
Topics
Industries




